<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813539</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-110-1201</org_study_id>
    <nct_id>NCT01813539</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of ARGX-110 in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>arGEN-X BVBA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>arGEN-X BVBA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the recommended Phase 2 dose of ARGX-110, an
      antibody that binds CD70, in patients with advanced malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I study conducted in patients whose tumors express the target of interest. PK, PD,
      biomarkers will be determined to support dose selection.

      Phase II study conducted in CTCL patients who are CD70 positive. PK, PD, biomarkers and IHC
      will be determined to assess efficacy
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine optimal dose of ARGX-110 in patients with advanced malignancies by number of patients with dose-limiting toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>DLT defined as drug-related grade 3 or 4 Adverse Events (CTCAE criteria version 4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of AE by dose level</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse Events classified according to CTCAE Version 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of ARGX-110</measure>
    <time_frame>2 years</time_frame>
    <description>ARGX-110 blood levels will be measured using a validated method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of ARGX-110 biological activity</measure>
    <time_frame>2 years</time_frame>
    <description>Biomarkers will be measured in serum and on tumor samples to correlate systemic drug effects with AE and Tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who achieve a tumor response</measure>
    <time_frame>2 years</time_frame>
    <description>Response will be assessed according to RECIST.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Cancers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 1 : ARGX-110 intravenous administration every 3 weeks. No dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 2: ARGX-110 intravenous administration every 3 weeks. No dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 3: ARGX-110 intravenous administration every 3 weeks. No dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose level 4: ARGX-110 intravenous administration every 3 weeks. No dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTCL patients treated with dose level as cohort 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARGX-110</intervention_name>
    <description>Outpatient intravenous infusion, in step-wise increments, every 3 weeks.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years.

          -  Written informed consent prior to any study-related procedure, willing and able to
             comply with protocol-specified procedures and scheduled evaluations.

          -  Histological diagnosis of CD70 antigen positive malignancies refractory to, or
             relapsing after standard therapy.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

          -  Adequate haematological, hepatic, and renal function (absolute neutrophil count (ANC)
             &gt; 1.0 x 109/L; haemoglobin &gt; 90 g/L; platelet count ≥ 75 x 109/L; total bilirubin ≤
             1.5 x the upper limit of normal [ULN]; alanine transaminase [ALT] ≤ 3 x ULN or ≤ 5 x
             ULN for patients with liver metastases; serum creatinine ≤ 1.5 x the ULN).

        Exclusion Criteria:

          -  Prior allogeneic bone marrow transplantation.

          -  History or clinical evidence of neoplastic central nervous system (CNS) involvement.

          -  History of another primary malignancy that has not been in remission for at least 1
             year.

          -  Systemic glucocorticoid administration at doses greater than physiological replacement
             within 4 weeks of ARGX-110 first dose administration.

          -  Major surgery within 4 weeks of ARGX-110 first dose administration.

          -  Prior chemotherapy, biological therapy, radiation therapy with curative intent, or any
             experimental therapy within 4 weeks of ARGX-110 first dose administration.

          -  Unresolved grade 3 or 4 toxicity from prior therapy, including experimental therapy.

          -  Active, untreated viral, bacterial, or systemic fungal infection.

          -  History of human immunodeficiency virus (HIV) infection, persistent hepatitis B virus
             surface antigen (HBsAg), or hepatitis C virus (HCV) infection.

          -  Any clinical finding, including psychiatric and behavioral problems, which, in the
             opinion of the Investigator, precludes the patient from safely participating in the
             study.

          -  Childbearing potential unless using an adequate measure of contraception.

          -  Pregnancy or lactation.

          -  History of hypersensitivity to recombinant proteins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Awada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZA - Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZG - Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHLS</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave-roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &quot;L. e A. Seràgnoli&quot;</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

